Clinical Trials

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

BreastGastrointestinalGenitourinaryThoracic

298 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT00425555 2021-08-20

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

139 enrolled 21 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

129 enrolled 16 charts

Hodgkin Disease

NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

MyeloidOther hematologic neoplasm

27 enrolled 14 charts

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00445068 2021-07-14

Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

38 enrolled 13 charts

Multiple Myeloma

NCT00667862 2021-06-21

Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer

35 enrolled 8 charts

LymphoidOther hematologic neoplasmPlasma cell

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00621244 2021-01-05

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

Phase 1/2 Completed

175 enrolled 25 charts

Leukemia, Lymphoma, Multiple Myeloma

NCT00493766 2020-12-19

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Phase 1 Terminated

16 enrolled

Prostatic Neoplasms

NCT00503451 2020-12-19

A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors

14 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT00532389 2020-12-19

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

62 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00532675 2020-12-19

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

46 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00535951 2020-12-19

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

18 enrolled

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mesothelioma

NCT00570284 2020-12-19

A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

36 enrolled

Tumor-Agnostic

Neoplasms

NCT00663832 2020-12-19

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

44 enrolled

Neoplasms, Prostatic Neoplasms

NCT00739414 2020-12-19

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

14 enrolled

Tumor-Agnostic

Neoplasms

NCT00788931 2020-12-19

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

15 enrolled

Breast

Breast Neoplasms

NCT00997399 2020-12-19

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

37 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01007968 2020-12-19

Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function

25 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT01055483 2020-12-19

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

59 enrolled

Leukemia, Myeloid, Acute

NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

46 enrolled

Chromosome Aberrations, Leukemia, Myeloid, Acute

NCT01613976 2020-12-19

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

MyeloidOther hematologic neoplasm

10 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00946647 2020-08-04

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Phase 1/2 Completed

113 enrolled 21 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01802879 2019-12-06

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

9 enrolled 8 charts

Hematologic Neoplasms

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT02720510 2018-07-24

PANORAMA4

6 enrolled 7 charts

Multiple Myeloma

NCT01083602 2017-12-21

MACS1271

55 enrolled 11 charts

Multiple Myeloma, Recurrence

NCT00670553 2017-05-17

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

GastrointestinalGenitourinaryHead & Neck

7 enrolled

Esophageal Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT00880269 2017-02-23

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

59 enrolled 7 charts

Leukemia, Leukemia, Myeloid, Acute

NCT02756663 2016-11-08

PANORAMA-5

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

NCT01034163 2016-07-07

PATH

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

NCT00567879 2016-05-09

A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab

Phase 1/2 Terminated

56 enrolled 5 charts

Breast

Breast Neoplasms

NCT00743288 2014-05-08

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Phase 1/2 Completed

40 enrolled 10 charts

Multiple Myeloma

NCT00412997 2012-11-27

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

14 enrolled

DermatologicLymphoid

Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00699296 2012-11-27

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

DermatologicLymphoidOther hematologic neoplasm

4 enrolled

Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00472368 2012-05-01

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

4 enrolled

Lymphoma

NCT00419536 2010-04-08

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Phase 1 Terminated

108 enrolled